VYLOY (zolbetuximab) for the Treatment of Gastric Cancer, Japan
VYLOY™ (zolbetuximab) is the first and only CLDN18.2-targeted therapy approved for the treatment of gastric cancer.
F. Hoffmann-La Roche Ltd
Biotechnology and Healthcare Solutions
Subscribed
You have successfully submitted your enquiry. Someone from our company will respond ASAP
About Us
Hoffmann-La Roche Ltd (Roche) is a world leader in biotechnology and a top provider of in-vitro diagnostics and other innovative healthcare solutions. The company strives to develop healthcare solutions for cardiometabolic diseases, inflammatory bowel diseases, hematologic disorders, infectious diseases, cancer, neurological disorders, respiratory diseases, gynaecological diseases, and ophthalmic diseases. To develop new solutions that help patients live longer and lead better lives, the company endeavours to strengthen its R&D efforts and enter into partnerships with external players. The company offers its products and services to hospitals, commercial laboratories, healthcare professionals, researchers, and pharmacists.
Projects
ELAHERE for the Treatment of Ovarian Cancer, US
AbbVie acquired ImmunoGen in February 2024, which added ELAHERE to its portfolio.
Contact Details
Website
Email Address
Address
4070 Basel,
Switzerland
Switzerland
Phone
Regional Offices
Address
F. Hoffmann-La Roche Ltd
4070 Basel
Switzerland